<span item_type="fundamental" item_id="66358c2277df1fcef8edb63a2c73c072" counter_id="ST/US/RVPHW" env="prod"></span><span item_type="announcement" item_id="549450627807055489" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -0.12.</p><p>EBIT: As of FY2025 Q2, the actual value is USD -6.073 M.</p><p></p><h3>Financial Results for June 30, 2025</h3><h4>Net Loss</h4><ul><li>The Company reported a net loss of approximately $6.1 million, or $0.12 per share, for the three months ended June 30, 2025, compared to a net loss of approximately $7.9 million, or $0.26 per share, for the three months ended June 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li></ul><h4>Cash and Cash Equivalents</h4><ul><li>As of June 30, 2025, the Company’s cash and cash equivalents totaled approximately $10.4 million compared to approximately $13.5 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li></ul><h4>Operating Expenses</h4><ul><li>Research and development expenses were $3.7 million for the three months ended June 30, 2025, compared to $5.6 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li><li>General and administrative expenses were $2.3 million for the three months ended June 30, 2025, compared to $2.5 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li><li>Total operating expenses were $6.1 million for the three months ended June 30, 2025, compared to $8.1 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li></ul><h4>Loss from Operations</h4><ul><li>Loss from operations was $6.1 million for the three months ended June 30, 2025, compared to $8.1 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li></ul><h4>Other Income (Expense)</h4><ul><li>Gain on remeasurement of warrant liabilities was $11,126 for the three months ended June 30, 2025, compared to $200,273 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li><li>Interest expense was $4,797 for the three months ended June 30, 2025, compared to $5,153 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li><li>Interest income was $22,847 for the three months ended June 30, 2025, compared to $87,610 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li><li>Other (expense) income, net was -$1,850 for the three months ended June 30, 2025, compared to -$5,621 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li></ul><h4>Total Other (Expense) Income, Net</h4><ul><li>Total other (expense) income, net was $27,326 for the three months ended June 30, 2025, compared to $277,109 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li></ul><h4>Loss Before Provision for Income Taxes</h4><ul><li>Loss before provision for income taxes was $6.0 million for the three months ended June 30, 2025, compared to $7.9 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li></ul><h4>Provision for Income Taxes</h4><ul><li>Provision for income taxes was $7,954 for the three months ended June 30, 2025, compared to $7,385 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li></ul><h4>Net Loss</h4><ul><li>Net loss was $6.1 million for the three months ended June 30, 2025, compared to $7.9 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Planned meeting with FDA to discuss brilaroxazine’s path to approval in Q4 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li><li>Potential NDA submission for brilaroxazine in schizophrenia targeted in Q2 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li><li>Investigational new drug application (IND) submission for liposomal-gel formulation of brilaroxazine in psoriasis expected by Q2-2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm"></span></li></ul>

Reviva Pharmaceuticals - CW23 | 8-K: FY2025 Q2 EPS: USD -0.12